IMRIS has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the new Invision 3T Recharge Operating Suite
IMRIS imaging, who design intraoperative MRI systems for imaging during neurosurgical procedures, has announced that the company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the new Invision 3T recharge operating suite
The Invision 3T recharge is a ceiling-mounted intraoperative MRI system designed for diagnostic and intraoperative imaging.
The new operating suite provides an upgrade path for other IMRIS suites that are currently using Siemens' MAGNETOM Verio magnets, enabling them with the latest capabilities of Siemens' MAGNETOM Skyra fit upgrade.
“We’re delighted to be able to offer our IMRIS customers currently using the Siemens Verio platform this significant upgrade to their InVision System,” said IMRIS CEO Marc Buntaine.
He added: “The InVision 3T Recharge brings the latest state-of-the-art Siemens Skyra Fit Biomatrix technology to an IMRIS Operating Suite, extending the life of the initial investment and enabling IMRIS intraoperative MRI value to be enhanced at these clinical centres.”
IMRIS customers can take advantage of the newest Siemens MRI technology, including improved diagnostic image quality, thanks to the upgrade platform.
Workflows are streamlined, productivity can increase, and scan times are reduced due to the AI-powered imaging protocols and automatic image reconstruction post-processing managed as a background activity.
